Stock Information

Relmada Therapeutics is focused on developing novel and innovative treatments for the improvement of human health. 

Our lead program NDV-01, is a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with non-muscle invasive bladder cancer; the sepranolone program, a neurosteroid epimer of allopregnanolone, is Phase 2b-ready for the potential treatment of Prader-Willi Syndrome, and other compulsivity-related disorders.

We are continuously evaluating new programs, developing the company through strategic product acquisition and pursuing our goal to maximize shareholder value.  

Relmada Therapeutics, Inc. was founded in 2004 and is headquartered in Coral Gables, Florida.